Univariable logistic regression for predictors of cardiac response at 90 days
| Variables . | Odds ratio . | 95% CI . | P . |
|---|---|---|---|
| Sex, male | 0.64 | 0.25-1.62 | 0.349 |
| NYHA class I | 1.13 | 0.35-3.70 | 0.835 |
| Troponin I > 0.500 ng/mL | 1.02 | 0.31-3.30 | 0.974 |
| eGFR < 30 mL/min × 1.73 m2 | 0.90 | 0.32-2.54 | 0.845 |
| LC isotype κ vs λ | 0.53 | 0.20-1.46 | 0.221 |
| dFLC > 50 mg/L | 0.21 | 0.05-0.82 | 0.024 |
| dFLC > 180 mg/L | 0.56 | 0.22-1.41 | 0.217 |
| dFLC > 500 mg/L | 0.97 | 0.30-3.13 | 0.959 |
| BMPC > 10% | 0.23 | 0.06-0.94 | 0.040 |
| Bortezomib-based treatment, yes | 1.13 | 0.45-2.86 | 0.788 |
| Treatment with CyBorD, yes | 1.18 | 0.44-3.16 | 0.736 |
| Treatment with BMDex, yes | 0.90 | 0.24-3.34 | 0.875 |
| Treatment with MDex, yes | 0.96 | 0.37-2.48 | 0.933 |
| Variables . | Odds ratio . | 95% CI . | P . |
|---|---|---|---|
| Sex, male | 0.64 | 0.25-1.62 | 0.349 |
| NYHA class I | 1.13 | 0.35-3.70 | 0.835 |
| Troponin I > 0.500 ng/mL | 1.02 | 0.31-3.30 | 0.974 |
| eGFR < 30 mL/min × 1.73 m2 | 0.90 | 0.32-2.54 | 0.845 |
| LC isotype κ vs λ | 0.53 | 0.20-1.46 | 0.221 |
| dFLC > 50 mg/L | 0.21 | 0.05-0.82 | 0.024 |
| dFLC > 180 mg/L | 0.56 | 0.22-1.41 | 0.217 |
| dFLC > 500 mg/L | 0.97 | 0.30-3.13 | 0.959 |
| BMPC > 10% | 0.23 | 0.06-0.94 | 0.040 |
| Bortezomib-based treatment, yes | 1.13 | 0.45-2.86 | 0.788 |
| Treatment with CyBorD, yes | 1.18 | 0.44-3.16 | 0.736 |
| Treatment with BMDex, yes | 0.90 | 0.24-3.34 | 0.875 |
| Treatment with MDex, yes | 0.96 | 0.37-2.48 | 0.933 |
BMDex, bortezomib, melphalan, and dexamethasone; CyBorD, cyclophosphamide, bortezomib, and dexamethasone; LC, light chains.